ALVO:OMXICEAlvotech Analysis
Data as of 2026-08-22 - not real-time
$4.43
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Alvotech is neutral at $4.43, with no clear ordering between short and long averages. It has gained 35.1% over the past 30 days. RSI sits at 68.9, which reads as approaching overbought, and MACD momentum is bullish. The recent range runs from support at $3.05 up to resistance at $4.59.
On valuation the read is undervalued — earnings multiple of 17.8 versus a 31.1 sector average, below the peer group. The average analyst target implies 29.8% above today's level. Revenue is contracting at 38.9% on a -36.3% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 77.6%, a beta of 0.58 and a maximum drawdown of 66.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
On valuation the read is undervalued — earnings multiple of 17.8 versus a 31.1 sector average, below the peer group. The average analyst target implies 29.8% above today's level. Revenue is contracting at 38.9% on a -36.3% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 77.6%, a beta of 0.58 and a maximum drawdown of 66.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 4.16
- MACD momentum is positive
- 30-day price change of +35.1%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 17.8 versus sector average of 31.1
- Trading above the 200-day average of 4.16
- Analyst targets imply +29.8% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 17.8 versus sector average of 31.1
- Negative profit margin of -36.3%
- Analyst targets imply +29.8% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth-38.90%
Profit Margin-36.31%
P/E Ratio17.8
ROA2.19%
P/B Ratio-4.9
Op. Cash Flow$-198702000
Free Cash Flow$-123130128
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI68.9
Support$3.05
Resistance$4.59
MA 20$3.83
MA 50$3.68
MA 200$4.16
MACDBullish
VolumeStable
Fear & Greed Index94.41
Valuation
Target Price$5.75
Upside/Downside29.80%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.58
Volatility77.61%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.